PROBIAL Stomach

PROBIAL® Stomach has been specifically developed and clinically evaluated to improve symptoms of Functional dyspepsia (FD), a chronic gastrointestinal disorder - one of the four categories of functional GI disorders. FD affects 10% to 30% of adults worldwide and is categorized into two subgroups: Postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS) [1]. PDS is primarily characterized by postprandial fullness and early satiety, while EPS is distinguished by epigastric pain and burning sensations.

Standard treatments for FD typically involve acid suppressants (such as proton pump inhibitors and histamine type 2 receptor antagonists), prokinetics, and antacids [2]. In a clinical study, a 30-day supplementation with PROBIAL® Stomach, either as a standalone treatment or in conjunction with standard pharmacological therapies, showed significant improvement in dyspeptic symptoms in patients with FD [3].

Specifically, PROBIAL® Stomach alone led to the lowest prevalence of all symptoms post-treatment in PDS patients and notably reduced the incidence of all symptoms in EPS patients. Notably, when compared to a combination of PROBIAL® Stomach with standard pharmacological treatment, the use of PROBIAL® Stomach alone exhibited [3]:

• The highest prevalence of no postprandial filling symptoms, no epigastric burning, and no epigastric pain in PDS patients.

• The highest prevalence of no postprandial filling and no early satiety in EPS patients.